| Journey Medical is a commercial-stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Co.'s portfolio includes five branded and three authorized generic prescription drugs. Co.'s marketed products include: Qbrexza®, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane®, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Targadox®, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino®, an oral minocycline drug for the treatment of acne; and Exelderm® Cream and Solution, an antifungal intended for topical use. The DERM average annual return since 2021 is shown above.
The Average Annual Return on the DERM average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether DERM average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the DERM average annual return calculation with any dividends reinvested as applicable (on ex-dates).